Researchers from the pharmaceutical industry and academia use the TERIS database to guide scientific decisions on the maternal-fetal safety of new proprietary compounds. This is important because in 2015, the Food and Drug Administration made the decision to discontinue pregnancy risk letter categories. Since that time, the responsibility for communicating teratogenic risk on biological and pharmaceutical drug labels has shifted back to individual companies.
Determining the safety of medications during pregnancy is a dynamic, multi-layered task that requires access to authoritative information. TERIS is a specialized digital resource that provides expert guidance on teratogenic risk of over 1,700 medications and other environmental exposures including infections and vaccines. TERIS can be used to develop solid, data-driven text on fetal risks and should be considered an essential tool for communicating those risks on drug labels and packaging inserts.
TERIS is unique in that it is governed by an Advisory Board composed of global experts from the fields of medicine, epidemiology, and genetics. The Advisory Board carefully reviews agent summaries and all teratogenic risk ratings are generated by group consensus. The level of authoritative guidance that TERIS provides on teratogenic risk is unparalleled in the world.
Please see “About Us” for more information on the Advisory Board.
About our team
All agents are assigned a teratogenic risk rating by the TERIS Advisory Board. Each risk rating requires a consensus decision from the board. The TERIS Advisory Board is composed of subject-matter experts in teratology from the fields of medicine, public health, genetics and epidemiology.
Currently, there are more than 1,750 agents available on TERIS, including 200 of the most frequently prescribed drugs. In addition, TERIS provides an updated version of Shepard’s Catalog of Teratogenic Agents, which provides information on over 3,700 agents. Both systems are available online.